PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Konishi, Hiroaki ^a   Takagi, Akimitsu ^a   Kurita, Akinobu ^a   Kaneda, Norimasa ^a   Matsuzaki, Takeshi ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Ascites fluid; Drug delivery system; Ovarian cancer; Peritoneal metastasis; Spheroid culture

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; IHL 305; IRINOTECAN; LIPOSOME; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER INHIBITION; CANCER LOCALIZATION; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCITES; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; MICE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POLYETHYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867221976     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-462     Document Type: Article

References (30)

1. American Cancer Society Cancer Facts & Figures 2010 2010, Atlanta: American Cancer Society, American Cancer Society.
2. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010, 102:222-229. 10.1093/jnci/djp500, 2826180, 20110551.
3. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in woman with ovarian tumors of low malignant potential. Gynecol Oncol 2002, 86:34-37. 10.1006/gyno.2002.6711, 12079297.
4. Fung MF, Bryson P, Johnston M, Charmbers A. Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can 2004, 26:717-728.
5. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Bunger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43. 10.1056/NEJMoa052985, 16394300.
6. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996, 335:1950-1955. 10.1056/NEJM199612263352603, 8960474.
7. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:1001-1007.
8. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2007, 25:437-443. 10.1200/JCO.2006.07.3494, 17264340.
9. Piccart MJ, Bertelsen K, James K, Cassidy J, Manginol C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000, 92:699-708. 10.1093/jnci/92.9.699, 10793106.
10. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008, 122:91-99. 10.1002/ijc.23083, 17893878.
11. Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther 2008, 7:3441-3451. 10.1158/1535-7163.MCT-08-0417, 18852147.
12. Slack-Davis KK, Atkins KA, Harrer C, Hershey ED, Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 2009, 69:1469-1476. 10.1158/0008-5472.CAN-08-2678, 19208843.
13. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28:461-468. 10.1038/onc.2008.394, 18978815.
14. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009, 15:1133-1139. 10.1158/1078-0432.CCR-08-0905, 19228718.
15. Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 1998, 12:1035-1040.
16. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19:3439-3441.
17. Allen TM, Austin GA, Chonn A, Lin L, Lee KC. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta 1991, 1061:56-64. 10.1016/0005-2736(91)90268-D, 1995057.
18. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa O. Phase II study of CPT-11, a new Camptothecin derivative, in metastatic colorectal cancer. CPT-11 gastrointestinal cancer study group. J Clin Oncol 1993, 11:909-913.
19. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifiji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M. A new derivative of Camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992, 10:1225-1229.
20. Matsuzaki T, Takagi A, Furuta T, Ueno S, Kurita A, Nohara G, Kodaira H, Sawada S, Hashimoto S. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models. Oncol Rep 2012, 27:189-197.
21. Shmeeda H, Tzemach D, Mak L, Gabizon A. Her2-targeted pegylated liposomal doxorubicin: Retention of targetspecific binding and cytotoxicity after in vivo passage. J Control Release 2009, 136:155-160. 10.1016/j.jconrel.2009.02.002, 19331844.
22. Lin Y-Y, Chang C-H, Lu Y-C, Hwang J-J, Tseng Y-L, Lin W-J, Ting G, Wang H-E. Evaluation of pharmacokinetics of 111In-labeled VNP-PEGylated liposome after intraperitoneal and intravenous administration in a tumor/ascites mouse model. Cancer Biother Radiopharm 2009, 24:453-460. 10.1089/cbr.2008.0572, 19694580.
23. Liau S-S, Jazag A, Ito K, Whang EE. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. British J Cancer 2007, 96:993-1000.
24. McGuire WP, Hoskins WJ, Brady MF, Kugera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6. 10.1056/NEJM199601043340101, 7494563.
25. Takagi A, Watanabe M, Ishii Y, Morita J, Hirokawa Y, Matsuzaki T, Shiraishi T. Three-dimensional cellular spheroid formation provides human prostate tumor cell with tissue-like features. Anticancer Res 2007, 27:45-54.
26. Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol 2009, 66:43-52.
27. Estep AL, Palmer C, McComick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One 2007, 2:e1279. 10.1371/journal.pone.0001279, 2093994, 18060073.
28. Sako A, Kitayama J, Koyama H, Ueno H, Uchida K, Hamada H, Nagawa H. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res 2004, 64:3624-3628. 10.1158/0008-5472.CAN-04-0304, 15150121.
29. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary. Cancer 2000, 88:2584-9. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5, 10861437.
30. Ballard BE. Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J Pharm Sci 1968, 57:357-378. 10.1002/jps.2600570301, 4871917.